COVID-19 vaccine developer Inovio Pharmaceuticals (INO -9.6%) slumps on average volume in apparent response to a post on social media by short seller Citron Research that the stock is heading back to $5 a share, 68% below the current price of $15.47.
Shares peaked at $33.79 on June 26 during the COVID-19 vaccine-stoked rally.
Roth Capital is another bear, believing the candidate INO-4800 has “virtually no chance” of coming out on top of its many competitors.
Muddy Waters is yet another pessimist.
https://seekingalpha.com/news/3616555-inovio-pharma-under-pressure-on-bearish-citron-call
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.